Skip to content
Review

A-039 Ratio of Lipoprotein(a) orders to LDL-Cholesterol orders: A novel method to benchmark appropriate test utilization of Lp(a)

Oct 2026 · Clinical Chemistry · 0 citations

Abstract

Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease(ASCVD) and calcific valvular aortic stenosis. Traditionally, major guidelines recommended targeted Lp(a) measurement for patients with familial hypercholesterolemia, premature ASCVD, or individuals at moderate ASCVD risk to improve risk classification. Due to emerging evidence of the significant atherosclerotic risk posed by Lp(a), the consensus is towards universal screening. The European Society of Cardiology/European Atherosclerotic Society Guidelines, Canadian Cardiovascular Society Guidelines, and focused updates of National Lipid Association scientific statement recommended universal screening of Lp(a) level from the year 2019, 2021 and 2024 respectively. From laboratory stewardship perspective, it to challenging to assess the clinician’s concordance to the screening guidelines. We therefore propose benchmarking Lp(a) orders to LDL orders ratio as a surrogate to assess appropriate utilization. We reviewed the number of Lp(a) tests orders and LDL-C tests orders placed at our main hospital for a period of 5 years from 2021 to 2025. Data is extracted from laboratory information system. LDL-C is measured using a direct homogenous enzymatic colorimetric assay (Roche Diagnostics, Basel). Lp(a) was sent out to a local laboratory which uses a immunoturbidimetric assay method traceable to IFCC reference material SRM2B (Roche Diagnostics, Basel). We also studied the values of Lp(a), and the ordering specialty. Given that a typical patient will receive a LDL-Cholesterol test every 4 to 6 months (i.e. 2 to 3 LDL Cholesterol tests per year) over a period of up to 30 years under our institution care, at long term steady state, we expect a ratio of 1 Lp(a) to 60-90 LDL-C. There was a total of 73 Lp(a) orders during the 5 years period. The annual Lp(a) orders were 3, 1, 3, 22 and 44 from Year 2021 to 2025 respectively. For LDL-C, the annual orders were 29961, 29203, 27400, 27993 and 27605 from Year 2021 to 2025 respectively, making a ratio of 1 Lp(a) to 9987 LDL-C; 1:29203; 1:9133; 1:1272, 1:627 from Year 2021 to 2025 respectively. Overall 14 out of 73(19%) had Lp(a)>75nmol/L. In terms of ordering departments, 9(12%) were made by Cardiology, 57(78%) were ordered by Endocrinology, 7(10%) were ordered by other departments. 4 out of 9 orders(44%) from Cardiology had Lp(a)>125nmol/L compared to 9 out of 57(15%) from Endocrinology. However this was not statistically significant (Chi-squared value=9.179, p=0.0568). The ordering ratio of Lp(a) to LDL-C at our institution was inappropriately low, though it has improved from 1:9987 to 1:627. This is far from the 1:60 ratio that we define as appropriate for lifetime universal screening, and may indicate significant underscreening of Lp(a) at our institution given the widespread availability of treatment. FDA approved PCSK9 inhibitors can lower Lp(a) by 25%. The advent of small interfering RNA and antisense oligonucleotide drugs for Lp(a) may provide further actionable steps to optimize patient outcomes. From laboratory perspective, moving from a pure provider of service to laboratory stewardship is integral for laboratorians to add value to clinical care. Baseline data serve as the starting point for quality improvement initiatives.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.